论文部分内容阅读
目的:观察复方苦参注射液对肺癌恶性胸水CA125指标影响的临床疗效。方法:免疫发光法监测血清、胸水中肿瘤标志物全套(CEA、AFP、CA125、CA153、CA199)含量。秩和检验比较胸水中CA125在复方苦参注射液灌注胸腔前后的变化。结果:血清与胸水中肿瘤标志物指标阳性率一致(100%)。胸水肿瘤标志物指标含量是血清中的1~3倍以上。经复方苦参注射液胸腔灌注治疗后胸水中CA125指标含量明显低于治疗前(P<0.01)。结论:复方苦参注射液有降低肺癌恶性胸水中CA125指标含量的作用,提示其在一定程度上有控制癌性胸水生长速度的作用。
Objective: To observe the effect of Fufang Kushen injection on CA125 of malignant pleural effusion in patients with lung cancer. Methods: Immunohistochemistry was used to detect the levels of tumor markers (CEA, AFP, CA125, CA153 and CA199) in serum and pleural effusion. Rank sum test was used to compare the changes of CA125 in pleural effusion before and after perfusion of thoracic cavity with Compound Kushen injection. Results: The positive rate of tumor markers in serum and pleural effusion was consistent (100%). Pleural effusion tumor markers index content is 1 to 3 times higher in serum. The content of CA125 in pleural effusion after compound Kushen injection was significantly lower than that before treatment (P <0.01). Conclusion: Compound Kushen injection can reduce the content of CA125 in malignant pleural effusion of lung cancer, suggesting that it may control the growth of cancerous pleural effusion to a certain extent.